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EFFICACY AND COST-
EFFECTIVENESS OF BRONCHIAL 
A RTERIAL EMBOLI~ATION IN THE 
TREATMENT OF MAJOR 
H AEMOPTYSIS 
Peter Corr, David Blyth, Charles Sanyika, Duncan Royston 
Objective. To determine the efficacy and cost-effectiveness of 
bronchial artery embolisation (BAE) in the treatment of major 
and massive haemop tysis in lllV-positive and negative 
patients with pulmonary inflammatory disease. 
Methods. A retrospective review of patients admitted over a 
period of 24 months to Wentworth Hospital with major 
haemop tysis treated using BAE. 
Results. Eighty-seven patients were treated (77 males, 10 
females). Bilateral disease was present in 50 patients (57%). 
Thirty-two patients were lllV-positive (37%). Embolisation 
was successfully performed in 77 patients (88.5%), and failed 
for .technical reasons in 10 patients (11 .5%). There was only 
one procedural complication. Fifty-seven patients had a 
successful outcome, with cessation of haemoptysis within 24 
hours (66.5%). Haemoptysis continued in 30 patients (34%) 
(20 patients embolised and the 10 patients who had failed 
procedures). Fourteen of these patients (16%) required 
lobectomy or pneumonectomy as an emergency procedure. 
Five patients (5.7%) died from respiratory failure or 
pulmonary haemorrhage. Twenty-four HIV-positive patients 
were successfully embolised. Costing of BAE, including a 
2-day ICU and 3-day ward stay, was R6 720; together with 
surgical resection the cost was R14 170. 
Conclusions. BAE is an effective treatment for major and/or 
massive haemoptysis in patients with pulmonary 
inflammatory disease who are not surgical candidates. 
Patients who are HIV-positive are able to tolerate the 
procedure well. 
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Massive haemoptysis is defined as blood loss exceeding 600 rnl 
over 24 hours or haemoptysis exceeding 250 rnl in one episode, 
and sufficiently severe to require admission to an intensive care 
unit (ICU). Untreated massive haemoptysis has a mortality rate 
exceeding 50%.1 Major haemoptysis includes massive 
haemoptysis and those patients with ongoing haemoptysis 
considered at risk of life-threatening haemoptysis. Bronchial 
arterial embolisation (BAE) has become the treatment of choice 
to stabilise the patient before surgical resection of the bleeding 
region.' Embolisation is also used as a definitive treatment in 
those patients who are not surgical candidates.3 BAE is effective 
in stopping haemoptysis in 75- 90% of patients,• 
We have used BAE at Wentworth Hospital, Durban, to treat 
haemoptysis from inflammatory lung disease. The spectrum of 
patients has changed over the last 5 years with the rapid 
increase in the incidence of PTB associated with HlV infection 
in KwaZulu-Natal.' 
The purpose of this study was to determine the efficacy and 
cost-effectiveness of BAE in the treatment of massive 
haemoptysis in pulmonary inflammatory disease patients with 
and without mv infection. 
M ETHODS 
We retrospectively reviewed the case notes, chest radiographs, 
computed tomography (CT) scans and bronchial angiograrns of 
all patients who had BAE performed at Wentworth Hospital, a 
400-bed tertiary referral centre for cardiothoracic disease, from 
January 1997 to December 1998. Wentworth Hospital is the 
only referral centre for cardiothoracic patients in KwaZulu-
atal, which has an estimated population of 8.5 million people. 
We recorded the following data: demographic information, 
length of hospital stay, aetiology of infection or pulmonary 
pathology, extent of disease on chest rad iograph and/or CT of 
the lungs, HIV status, surgical procedures, and outcome. 
Outcome ~as considered successful if the haemoptysis stopped 
or markedly decreased within 24 hours of the procedure. The . 
procedure was considered a failure if the haemoptysis 
continued after 24 hours or if an emergency surgical lung 
resection had to be performed. 
We determined the direct costs of the hospital stay including 
intensive care, the cost of investigations such as the full blood 
count, sputum an.alysis, bronchoscopy, CT of the lungs, the cost 
of the embolisation procedure, the cost of drugs and blood 
products given during the hospital stay and the cost of surgical 
procedures. HlV testing was carried out with the full informed 
consent of the patient. All patients underwent bronchial 
arteriography followed by embolisation. The decision to 
perform embolisation was made by the cardiothoracic surgeon 
(DB) on the basis of massive haemoptysis, i.e. more than 
600 ml of blood over 24 hours (5 cupfuls), or the presence of 
ongoing haemoptysis in the presence of active tuberculosis or 
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non-resectable pulmonary disease. Pulmonary disease was 
assessed as not surgically treatable if the patient had poor 
pulmonary function or when high-resolution CT (HRCT) 
confirmed bilateral and extensive disease. HRCT was 
performed on all patients except those few who haq respiratory 
failure and extensive bilateral disease and who were too 
dyspnoeic to lie supine in the scanner. HRCT was used to 
identify areas of bleeding. If bronchial embolisation was not 
technically possible or if it failed, emergency pulmonary 
resection of the affected lung was performed if feasible. 
We performed the bronchial arteriograrns with digital 
subtraction angiography (Toshiba, Japan) using a standard 
technique of femoral arterial puncture and selective 
catheterisation of the bronchia and internal thoracic arteries 
bilaterally.• The technique was performed by three authors 
(PC, CS, DR) as well as a number of registrars undergoing 
training who were supervised by the authors. Selective 
catheterisation of the internal thoracic arteries is important. 
Pleural involvement due to chronic tuberculosis commonly 
recruits collateral feeders from these arteries. The bronchial and 
internal thoracic arteries were embolised routinely if there was 
evidence of a vascular blush on contrast injection or if the 
arteries were hypertrophied. The end points of pulmonary 
vascular blush and arterial hypertrophy were easy to identify 
and there was no inter-observer variation in the detection of 
these end points between authors. We embolised all regions of 
the lungs that demonstrated hypervascularity after contrast 
injection. We did not embolise the artery if there was a 
contribution to the anterior spinal artery. We used polyvinyl 
particles, 500 - 750 microns in diameter, suspended in contrast 
(Contour, ycomed, Paris, France and Trufill, Cordis, USA) as 
the embolic agent of choice. 
R ESULTS 
Eighty-seven patients were identified who had had bronchial 
embolisation over the 24-month period. There were 77 male 
and 10 female patients, with a mean age of 38 years (standard 
deviation (SD) 12.5). The aetiology of the pulmonary disease is 
recorded in Table I. In 50 patients (57%) the disease process 
involved both lungs. Thirty-two patients (37%) were 
seropositive for ffiY, with 10 patients positive in 1997 and 22 
patients positive in 1998. CD4 count were not available for 
most patients because of the cost. 
Embolisation was successful in 77 patients (88.5%) (Fig. 1). 
Embolisation could not be performed in 10 patients (11 .5%) 
because of technical reasori , usually due to the bronchial 
arteries being too small for selective catheterisation. The 
embolisation procedure took between 30 and 60 minutes, with 
a mean of 45 minutes, depending on the level of expertise of 
the radiologist and the difficulty of selectively catheterising the 
bronchial arteries. There wa one procedure-related 
complication. This was an intimal flap which was raised at the 
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Table I. Aetiology of pulmonary disease 
Aetiology Number 
















57 successful 20 rebleeds 3 died 7 surgery 
7 surgery 2 died 
11 stabilised 
Fig. 1. Patients' immediate outcome. 
femoral artery puncture site of one patient resulting in 
temporary cessation of blood flow to the leg, but this resolved 
completely within 24 hours. 
Fifty-seven patients (65.5%) had a successful outcome, with 
haemoptysis resolving or being markedly reduced within 24 
hours. Thirty patients (34%) continued to bleed. Twenty of 
these patients were from the embolised group and 10 were 
from the group in which embolisation failed for technical 
reasons. Fourteen patients (16%) who continued to bleed after 
24 hours required emergency lobectomy or pneumonectomy. 
Sixteen patients were not offered any surgical procedure; 5 of 
these patients (5.7%) died, while 11 stabilised. The deaths 
occurred mainly within 48 hours of respiratory failure and / or 
pulmonary haemorrhage. Of the 32 patients who were 
seropositive for HIV, 24 (75%) were successfully treated using 
embolisation, 7 had persistent haemoptysis and 1 died. 
The mean hospital stay for patients who were not 
undergoing surgery was 5 days. Patients were followed up at 
the thoracic clinic, usually within 2 weeks, and only 12 patients 
(14%) were followed up for 1 month after the procedure. At the 
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Table II. Costing 
Cost (R) Total cost of st -y (R) 
Hospitalisation 
Ward bed 400/ day x 2 days 800 
!CUbed 800/ dayx 3 days 2400 
Total 3 200 
Medical treatment 
Drugs 100 500 
Blood 350 per unit 1050 
Total 1550 
Investigations 
Full blood count 50 
Sputum AFB culture 50 
Lung function test 20 
HIV test 20 
Total 140 
Imaging 




Bronchial angiogram 500 









AFB = acid-fast bacillus. 
follow-up clinic 32 of the 57 patients (56%) who were 
embolised successfully were reviewed. Haemoptysis had 
stopped completely in 20 patients and was red uced 
consid erably in 12. 
The costing of the procedure, surgical operations, 
hospi talisa tion, drugs and blood products are recorded in Table 
II. Professional fees were included in procedural costs. Total 
costs for the embolisation p~ocedure were R6 720 per hospital 
stay, with a mean of 2 days in the ICU, compared with the cost 
of surgical resection at R12 920. If surgery was performed after 
failed embolisation the cost increased to 
R14 170 per s tay. 
D ISCUSSIO N 
BAE is an effective treatment for major (including massive) 
haemoptysis. In almost two-thirds of our patients haerrioptysis 
stopped or was markedly reduced by this procedure. These 
results are similar to those of other large series'-".7 Over half of 
our patients had active PTB, their sputum being positive for 
acid-fast bacilli, w ith the other one-third of the patients 
suffering from chronic bronchiectasis. The number of pa tients 
who were seropositive for HIV d oubled over the 2 years of this 
s tudy, from 10 patients in 1997 to 22 pa tients in 1998. The fac t 
that patients were seropositive for HIV and had PTB d id not 
appear to affect the outcome of embolisation . There is no d oubt 
tha t patients who are HIV-posi tive derive the same benefi t 
from this procedure as HIV-nega tive patients. This p rocedure 
may be both life-saving and cost-effective. The true prevalence 
of HIV seroconversion in our patient cohort is not known as 
HIV testing can only be performed with the patient's written 
p ermission. It would be of interest to correla te outcome with 
CD4 counts to gauge the effect of immunodepression on the 
procedural outcome. We do not know the long-term outcome 
of our pa tients - many patients were lost to follow-up as they 
came from rural hospi tals. Twenty-nine per cent of patients 
continued to experience ongoing haemoptysis immedia tely 
after embolisation . Patients wi th chronic pulmonary 
inflammatory disease, especially chronic TB, develop 
hypervascular collaterals from the internal mammary arteries, 
subclavian artery branches, in tercostal arteries and even 
aneurysms from the pulmonary arteries. Unless all these 
collaterals are identified before embolisation, rebleeding is 
likely. This may make the procedure time-consuming, 
especially if the radiologist does not have experience in 
selective angiography. Bronchial anatomy is highly variable 
and angiographers have to be aware of the common norma l 
variants, especially ectopic bronchial arteries which can occur 
in 10% of patients, usually from the apex of the aortic arch.8•9 
The complications of BAE are well recorded in the 
literature.'·7 BAE is a safe procedure in experienced hands. Tne 
most serious complication is spinal cord ischaemia caused by 
inadvertent embolisation of the radiculomedullary and 
radiculopial branches arising from the intercostal and bronchial 
arteries. In this series such feeders to the spinal cord were only 
encountered in one patient, so precluding embolisation. 
Embolisation is a cost-effective procedure in the short term · · 
compared with lobectomy or pneumonectomy. However, to be 
used effectively radiologists must be trained in this . 
interventional technique, have good angiography facilities and 
use the correct embolic materials. We have found BAE to be a 
safe, effective and cost-effective procedure in those patients 
with severe haemoptysis caused by acute and chronic 
pulmonary inflammatory disease. Patients who are HIV-
positive appear to tolerate the procedure as well as HIV-
negative patients, and show a similar response to embolisation. 
We would encourage the use of BAE in those patients who are 
not surgical candidates, and believe that more radiologists in 
southern Africa should learn this procedure and become 
comfortable in performing BAE as an emergency procedure. 
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A NEW COMBINED DTP-HBV-
HIB VACCINE- STRATEGY FOR 
INCORPORATION OF HIB 
VACCINATION INTO CHILDHOOD 
IMMUNISATION PROGRAMMES 
A Ramkissoon, H M Coovadia, P Jugnundan, P Willems, 
B R Clemens 
Objectives. To evaluate the immunogenicity and reactogenicity 
of a pentavalent vaccine prepared by extemporaneously 
mixing diphtheria-tetanus pertussis-hepatitis B vaccine (DTP-
HBV) and lyophilised Haemophilus influenwe type B (Hib)-
tetanus conjugate vaccines in the same syringe, compared 
with the same vaccines given as separate, concomitant 
administrations. 
Design. Open, randomised comparative study. 
Setting. Durban, South Africa. 
Subjects. A total of 120 healthy male and female infants were 
enrolled in the trial and randornised into two groups; group 1 
received the combined administration (DTP-HBV-Hib), and 
group 2 received separate administrations of DTP-HBV and 
Hib vaccines. Vaccines were given as a three-dose primary 
vaccination course at 6,10 and 14 weeks of age. 
Outcome measures. Antibody levels were measured using 
standard techniques and local and general solicited 
symptoms were recorded using diary cards. 
Results. All subjects had seroprotective titres against 
diphtheria and tetanus; and antipolyribose-ribitol phosphate 
(PRP) titres 2:: 0.15 )lg/ ml1 month after the final dose. A 
vaccine response (defined as post-vaccination titres 
2:: 15 ELISA (EL).U/ ml in initially seronegative subjects; and 
as post- vaccination titres;::: pre-vaccination titres in initially 
seropositive subjects) against the pertussis component was 
seen in 83% and 85% of subjects in the groups receiving 
combined and separate administration. o differences were 
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